At ELRIG 2025, Bree Foster spoke to Jordan Lane and Layla Hosseini-Gerami about our unique drug turnaround process.
"By focusing on drugs that already show promise, Ignota Labs aims to accelerate development timelines, improve safety, and reduce carbon emissions by up to 80 percent compared with traditional drug discovery."
"We use our AI to map the mechanistic pathway of what's happened and why. If we can understand it, we can know what to change in the drug molecule. We can then buy or partner with the drug holders and develop a new clinical candidate, pushing it back into the clinic as quickly as possible."
"Most startups focus on creating entirely new drugs, however, Ignota has chosen to concentrate on refining existing candidates that others have left behind. By bringing failed drugs back to life, the company is not only exposing the untapped therapeutic potential of these molecules but also significantly reducing the time, cost, and environmental impact associated with traditional drug discovery."
Read more:
Can abandoned drugs still save lives? can be read in full at Drug Discovery News.
Published: 11 November 2025 by Drug Discovery News.
